Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors during the central anxious program, conolidine modulates alternate molecular targets. A Science Advances analyze uncovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By i... https://mariona320ejl5.blogdiloz.com/profile